CRISPR Therapeutics (NASDAQ:CRSP) used a fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline how the ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced ...
Peer-reviewed results in Molecular Therapy Oncology show that targeted, mutation-agnostic CRISPR gene editing of NRF2 in head and neck cancer models resensitizes treatment resistant tumors to ...
Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...
CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now ...
Casgevy, the company’s gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in fourth-quarter revenue and $116 million for the full year. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results